Machine intelligence for precision oncology
نویسندگان
چکیده
منابع مشابه
Future paradigms for precision oncology
Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular ...
متن کاملAn Emerging Role for Radiation Oncology in Precision Oncology
Article history: Received 1 March 2016 Accepted 1 March 2016 Available online 4 March 2016 the precision of radiotherapy delivery (e.g. computational algorithms, IMRT, IGRT, SBRT); and3. Incorporationof novel radiosensitizing andmolecular targeting agents with radiation therapy to reduce mechanisms of radiation resistance (e.g. epithelial growth factor receptor inhibitors and RT in head and nec...
متن کاملPrecision oncology: an overview.
In this Special Series issue, Journal of Clinical Oncology presents a systematic assessment of cancer genomic information and its accelerating clinical impact. In the scientific literature and lay press, the relevant discipline is often called personalized, or precision, cancer medicine. The word personalized conveys the sense that cancer genomic data may facilitate rational treatment choices t...
متن کاملActionability and precision oncology.
Cancer is driven by molecular aberrations that allow oncogenic cells to thrive by growing and eventually metastasizing, and/or by alterations in the tumor or host that are permissive for immune evasion. The development and availability of clinical-grade molecular diagnostic tests that interrogate the genomic portfolio of each patient's tumor, together with the clinical development of a myriad o...
متن کاملTargeting HER2: precision oncology for colorectal cancer.
www.thelancet.com/oncology Vol 17 June 2016 685 Advanced colorectal cancer still has a poor prognosis and more active drugs are urgently needed. HER2 was investi gated as a target in colorectal cancer in two early trials of trastuzumab plus chemotherapy as fi rst, second or third line therapy, which produced interesting but confl icting results. In The Lancet Oncology, Andrea Sartore-Bianchi an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Translational Medicine
سال: 2021
ISSN: 2220-6132
DOI: 10.5528/wjtm.v9.i1.1